Opinion|Videos|March 6, 2025
Key Takeaways From the PACIFIC-2 Trial: The Role of Concurrent Immunotherapy With CRT
The discussion explores promising future directions for managing locally advanced disease, focusing on combination immunotherapy approaches and the ongoing trials investigating their efficacy, as well as the potential role of combining chemotherapy (CRT) with immunotherapy in treatment regimens.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Briefly discuss the potential role of combination therapy in the consolidation setting. Where may this fit in the treatment paradigm?
Advertisement
Related to this article
The FDA approved imlunestrant plus abemaciclib in breast cancer and photodynamic therapy in skin cancer, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The phase 3 REZILIENT3 trial met its primary end point at a pre-specified interim analysis, with a median PFS of 14.5 months and a 65.0% ORR.
The FDA has cleared an sNDA updating the taletrectinib (Ibtrozi) label with new DOR data in TKI-naive patients with locally advanced or metastatic ROS1-positive NSCLC.
Cesalatamig earned FDA fast track designation for NSCLC that progressed after immunotherapy and platinum-based chemotherapy.
The phase 2 AMIGO-1 trial met its end point, with an 18-month PFS rate of 66.7% for first-line amivantamab, lazertinib, and pemetrexed in EGFR-mutant NSCLC.
First-line osimertinib plus gefitinib produced an 82.1% response rate and blocked second-site EGFR resistance mutations, but missed feasibility criteria.
KST-6051 received FDA fast track designation for KRAS-mutant solid tumors.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Imlunestrant Plus Abemaciclib for ER+, HER2–, ESR1-Mutated Metastatic Breast Cancer
2
EU Approval Reccomended by CHMP for Senaparib in First-Line Advanced Ovarian Cancer
3
CHMP Backs Perioperative Pembrolizumab Plus Enfortumab Vedotin for Resectable MIBC
4
Dr Gilbert on the Efficacy of Relacorilant Plus Nab-Paclitaxel in Ovarian Cancer
5